Insulin-like growth factor-1 and retinopathy of prematurity: A systemic review and meta-analysis

Surv Ophthalmol. 2023 Nov-Dec;68(6):1153-1165. doi: 10.1016/j.survophthal.2023.06.010. Epub 2023 Jul 7.

Abstract

The prevalence of retinopathy of prematurity (ROP) is rapidly increasing worldwide. Many researchers have explored the relationship between insulin-like growth factor-1 (IGF-1) and ROP; however, the results are controversial. This meta-analysis evaluates the correlation between IGF-1 and ROP systematically. We searched for PubMed, Web of Science, Embase, the Cochrane Central Register of Controlled Trials, Ovid MEDLINE, SinoMed, ClinicalTrials.gov, and 3 Chinese databases up to June 2022. Then, the meta-regression and subgroup analysis were carried out. Twelve articles with 912 neonates were included in this meta-analysis. The results revealed that 4 of 7 covariates account for significant heterogeneity: location, measurement method of IGF-1 levels, collection time of blood sample, and the severity of ROP. The pooled analysis showed that low IGF-1 levels could serve as a risk factor associated with the development and severity of ROP. Serum IGF-1 monitoring in preterm infants after birth will be helpful in the diagnosis and treatment of ROP, and the reference value of IGF-1 should be standardized according to the measurement of IGF-1 and the region, as well as the postmenstrual age of prematurity.

Keywords: IGF-1; Meta-analysis; ROP; Systemic review.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review

MeSH terms

  • Humans
  • Infant, Newborn
  • Infant, Premature*
  • Insulin-Like Growth Factor I / analysis
  • Retinopathy of Prematurity* / diagnosis
  • Retinopathy of Prematurity* / epidemiology
  • Retinopathy of Prematurity* / etiology
  • Risk Factors

Substances

  • Insulin-Like Growth Factor I